Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Go back to Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting| (NASDAQ: EDIT) | Delayed: 2.76 -0.04 (1.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.80 | 52 Week High | $43.99 | |||
| Open | $2.72 | 52 Week Low | $12.43 | |||
| Day High | $2.91 | P/E | N/A | |||
| Day Low | $2.72 | EPS | $0.00 | |||
| Volume | 1,372,434 | |||||
